A global pharmaceutical company focused on researching, developing, and commercializing innovative medicines, particularly in oncology and rare diseases. Investors track Daiichi Sankyo for its antibody-drug conjugate platform and partnerships with major drugmakers like AstraZeneca.
4 members of Congress have disclosed 11 trades in Daiichi Sankyo Company, Limited (DSNKY), a Healthcare company. The buy/sell breakdown shows 8 purchases versus 3 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-07-10 | Daniel Goldman | sell | $50K – $100K |
| 2018-09-27 | David P. Roe | buy | $1K – $15K |
| 2018-07-27 | David P. Roe | buy | $1K – $15K |
| 2018-07-19 | David P. Roe | buy | $1K – $15K |
| 2018-06-02 | David P. Roe | buy | $1K – $15K |
| 2018-02-01 | David P. Roe | buy | $1K – $15K |
| 2018-02-01 | David P. Roe | buy | $1K – $15K |
| 2015-03-31 | Harold Dallas Rogers | buy | $15K – $50K |
| 2012-01-10 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2012-01-10 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2008-11-11 | MICHAEL T. MCCAUL | buy | — |